Overview
The federal government has made a new determination under the Health Insurance Act 1973 that lists futibatinib - a cancer medicine - on the health insurance schedule. The determination is administered by the Department of Health, Disability and Ageing.
Listing period
The listing applies from 2 June 2026 through 7 September 2026. This is described as a short-term listing determination.
What the source does not specify
The source does not specify what condition or conditions futibatinib is approved to treat under this determination, nor what Medicare rebate amounts apply.
Relevance to small business
This rule governs the Medicare listing of a pharmaceutical. It does not affect business operations, employment, or tax obligations.
Full text
The full text of the determination is available at https://www.legislation.gov.au/F2026L00632.
This is a plain-English summary for information only, not legal or compliance advice. Always check the official source or consult a qualified professional.